Lip GY - Search Results

1

Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial.

Best JG, Arram L, Ahmed N, Balogun M, Bennett K, Bordea E, Campos MG, Caverly E, Chau M, Cohen H, Dehbi HM, Doré CJ, Engelter ST, Fenner R, Freemantle N, Hunter R, James M, Lip GY, Murray ML, Norrving B, Sprigg N, Veltkamp R, Zaczyk I, Werring DJ; OPTIMAS investigators. Best JG, et al. Among authors: lip gy. Int J Stroke. 2022 Jun;17(5):583-589. doi: 10.1177/17474930211057722. Epub 2022 Jan 12. Int J Stroke. 2022. PMID: 35018878

2

Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project.

Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Lip GY, et al. Stroke. 2002 Jan;33(1):238-42. doi: 10.1161/hs0102.101817. Stroke. 2002. PMID: 11779916

3

Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation.

Kamath S, Blann AD, Caine GJ, Gurney D, Chin BS, Lip GY. Kamath S, et al. Among authors: lip gy. Stroke. 2002 May;33(5):1237-42. doi: 10.1161/01.str.0000013739.82306.7f. Stroke. 2002. PMID: 11988597 Clinical Trial.

4

Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?

Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. Chung NA, et al. Among authors: lip gy. Stroke. 2002 Sep;33(9):2187-91. doi: 10.1161/01.str.0000023889.84649.3d. Stroke. 2002. PMID: 12215585 Clinical Trial.

5

Atrial fibrillation in the elderly: anticoagulation strategies and indications in the very elderly.

Kamath S, Lip GY. Kamath S, et al. Among authors: lip gy. Am J Geriatr Cardiol. 2002 Nov-Dec;11(6):357-62; quiz 363-4. doi: 10.1111/j.1076-7460.2002.00070.x. Am J Geriatr Cardiol. 2002. PMID: 12417841 Review.

6

Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?

Marín F, Roldán V, Climent V, Garcia A, Marco P, Lip GY. Marín F, et al. Among authors: lip gy. Stroke. 2003 May;34(5):1181-6. doi: 10.1161/01.STR.0000065431.76788.D9. Epub 2003 Mar 27. Stroke. 2003. PMID: 12663879

7

Ximelagatran for stroke prevention in atrial fibrillation.

Boos CJ, Lip GY. Boos CJ, et al. Among authors: lip gy. Expert Rev Cardiovasc Ther. 2005 Jul;3(4):551-63. doi: 10.1586/14779072.3.4.551. Expert Rev Cardiovasc Ther. 2005. PMID: 16076267 Review.

8

Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis.

Lip GY, Edwards SJ. Lip GY, et al. Thromb Res. 2006;118(3):321-33. doi: 10.1016/j.thromres.2005.08.007. Epub 2005 Sep 29. Thromb Res. 2006. PMID: 16198396 Review.

9

Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation.

Lip GY, Lane D, Van Walraven C, Hart RG. Lip GY, et al. Stroke. 2006 Sep;37(9):2294-300. doi: 10.1161/01.STR.0000236840.00467.84. Epub 2006 Aug 3. Stroke. 2006. PMID: 16888271

10

Atrial fibrillation and stroke prevention.

Kakar P, Lip GY. Kakar P, et al. Among authors: lip gy. Expert Rev Neurother. 2006 Oct;6(10):1523-30. doi: 10.1586/14737175.6.10.1523. Expert Rev Neurother. 2006. PMID: 17078791 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,959 results

Search Page